Episode Details

In this episode of Global Economic Press, Alex Brady explores a significant milestone in cardiovascular medicine: the 25th anniversary of the United States Food and Drug Administration's approval of vascular brachytherapy for treating in-stent coronary artery restenosis. This condition, which can cause arteries to re-narrow after stent placement, has seen improved outcomes thanks to the pioneering work of researchers like Doctor Paul Teirstein and Doctor Ron Waksman. Their early studies, conducted in collaboration with Best Medical International, laid the groundwork for the development of this innovative treatment. The episode highlights the journey from initial research to the landmark approval of the Novoste Beta-Cath System and Cordis's Iridium-192-based therapy in 2000, marking a new era in cardiovascular treatment.

Today, Best Vascular/Novoste, an affiliate of Best Medical International, continues to lead in the field of vascular brachytherapy. The company is committed to supporting the ongoing use of this technology and expanding its applications for future generations. As part of their efforts, they invite collaboration from clinicians, researchers, and partners to advance vascular brachytherapy and contribute to an upcoming publication scheduled for 2026. For more information about Best Vascular/Novoste and their initiatives, visit the TeamBest Global Companies website.